Topical Tranexamic Acid After Intravitreal Injections

Topical Use of Tranexamic Acid for Prevention of Subconjunctival Hemorrhage After Intravitreal Injections

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04400916

Enrollment

100

Registered

2020-05-26

Start date

2020-09-30

Completion date

2021-12-31

Last updated

2020-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subconjunctival Hemorrhage

Brief summary

We aim to investigate whether topical administration of Tranexamic acid can reduce the occurence of subconjunctival hemorrahge after routine intravitreal injections for retinal conditions.

Interventions

DRUGTranexamic acid

A single drop administered topically

OTHERBalanced Salt Solution

A single drop administered topically

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

Subjects receiving intravitreal injections as part of their routine ophthalmological care

Exclusion criteria

Pregnancy, Oral contraceptives/HRT use, Known systemic autoimmune disease, Renal failure, active/suspected infection or inflammation in the treated eye, subconjunctival hemorrahge prior to inclusion, History of subarachnoid hemorrahge, thromboembolic events, increased risk for thromboembolic events, known sensitivity to the study drug

Design outcomes

Primary

Measure	Time frame
Subconjunctival hemorrahge	3 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026